表紙
市場調査レポート

MediPoint:非血管ステントの世界市場の分析・予測

MediPoint: Non-Vascular Stents - Global Analysis and Market Forecasts

発行 GlobalData 商品コード 333929
出版日 ページ情報 英文 288 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
MediPoint:非血管ステントの世界市場の分析・予測 MediPoint: Non-Vascular Stents - Global Analysis and Market Forecasts
出版日: 2015年04月01日 ページ情報: 英文 288 Pages
概要

当レポートでは、世界の非血管ステントの市場について調査し、非血管ステントの分類、ステント留置の有効性、世界の主要地域におけるステント留置術の動向、市場参入環境、アンメットニーズ、市場成長推進因子・阻害因子および市場機会の分析、主要製品の比較分析、注目の臨床試験、ステント区分・地域別の手術件数およびステント売上の推移と予測、主要企業のプロファイルなどをまとめています。

第1章 目次

第2章 イントロダクション

第3章 産業の概要

  • 概要
  • ステント留置の分類
    • 腸内ステント
    • 膵臓・胆管ステント
    • 気道ステント
    • 尿管ステント
  • ステントのタイプと臨床的有効性
    • 腸内ステント
    • 膵臓・胆管ステント
    • 気道ステント
    • 尿管ステント
  • 処置の動向
    • 米国
    • EU5カ国
    • アジア太平洋
    • 南米
  • 市場アクセス
    • 製品の導入
    • 法規制
    • 償還
  • 法規制上の課題・リコール
  • M&A
  • 経済的影響

第4章 アンメットニーズ

  • 合併症への対処
  • ステント設計上の課題の解消
  • デリバリーシステムの簡素化
  • 産業および医師の関係の乖離
  • 特定症状専用のステント
  • 長期的・相対的臨床データの不足
  • パイプライン製品への再注目
  • 標準化の不足
  • コスト削減策
  • 国際的レジストリーのニーズ

第5章 市場機会の分析

  • ステントシステムの改善
  • 生分解性ステント
  • 薬剤溶出ステント
  • 放射線増感
  • カスタマイズステント
  • 新興市場

第6章 市場成長推進因子・阻害因子

第7章 競合評価

  • 消化管ステント
    • 概要
    • WallFlex (Boston Scientific Corporation)
    • Evolution (Cook Medical)
    • Niti-S (Taewoong Medical)
    • その他の主要上市済み消化管ステント
  • 胆管ステント
    • 概要
    • WallFlex Biliary RX (Boston Scientific Corporation)
    • Cotton-Leung (Amsterdam) (Cook Medical)
    • Bonastent (EndoChoice)
    • その他の上市済み胆管ステント
  • 気道ステント
    • 概要
    • Dumon (Novatech)
    • Aero/Aero DV (Merit Endotek)
    • Ultraflex (Boston Scientific Corporation)
    • その他の主要上市済み気道ステント
  • 尿管ステント
    • 概要
    • Polaris Ultra (Boston Scientific Corporation)
    • InLay Optima (C.R. Bard)
    • その他の主要上市済み尿管ステント

第8章 注目の臨床試験

  • 概要
  • 腸内ステント
  • 膵臓・胆管ステント
  • 気道ステント
  • 尿管ステント

第9章 現在・未来の企業

  • 企業戦略の動向
  • 企業プロファイル
    • Allium Medical
    • Boston Scientific Corporation
    • ConMed
    • Cook Medical
    • C.R. Bard
    • Ella-CS
    • Merit Endotek
    • M.I. Tech
    • Micro-Tech (Nanjing)
    • Medtronic (Covidien)
    • Novatech
    • オリンパス
    • Taewoong Medical
    • Xlumena
    • その他

第10章 市場予測

  • 企業の市場シェア
    • 米国
    • EU5カ国
    • 南米
    • アジア太平洋
  • 製品タイプ別市場
    • 世界市場の概要
    • 腸内ステント
    • 膵臓・胆管ステント
    • 気道ステント
    • 尿管ステント
  • 地域別市場
    • 世界市場の概要
    • 米国
    • EU
    • 南米
    • アジア太平洋

第11章 付録

図表

目次
Product Code: GDME0211MAR

Non-vascular stent technology has evolved over the years such that these devices are routinely used in clinical practice for different indications. Although it is a mature market, both short and long-term complications associated with non-vascular stents continue to persist. This report focuses on four market categories within the non-vascular stent segment, which includes enteral stents (esophageal, gastroduodenal and colonic stents), pancreatic and biliary stents, airways stents and urinary tract stents (ureteral, prostate and urethral stents). The overall non-vascular stent market has been estimated in this report, which covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India (10MM) up to 2021. The report provides an investigation of unmet needs, future adoption trends and compound annual growth rates (CAGR) for each geography and market segment. In addition, this report presents the current market drivers and barriers which will influence the future market growth of non-vascular stents in the 10MM.

Highlights

Key Questions Answered

  • What is the current and future non-vascular stent market outlook in the developed and emerging markets? (Q). What trends are affecting the global non-vascular stents market?
  • Which are the key, high growth markets that stent manufacturers should expand into? (Q). What non-vascular stent segments are growing the fastest?
  • There are a few significant unmet needs. (Q). What are these unmet needs? (Q). What is the scope for more innovation and what are the end-users looking for in their products?
  • Will biodegradable stent systems fulfill these unmet needs? (Q). What is physician perception and market outlook of this technology?
  • What percent of global profits are from emerging markets? (Q). How will this change in the future?
  • Boston Scientific currently dominates the global non-vascular stents market. (Q). What is their market share in the major global economies and which companies constitute the remainder of the market?

Reasons to buy

  • What Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading physicians and other stakeholders from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Overview
  • 3.2. Non-Vascular Stenting Indications
    • 3.2.1. Enteral Stents
    • 3.2.2. Pancreatic and Biliary Stents
    • 3.2.3. Airway Stents
    • 3.2.4. Urinary Tract Stents
  • 3.3. Types of Stents and Clinical Efficacy
    • 3.3.1. Enteral Stents
    • 3.3.2. Pancreatic and Biliary Stents
    • 3.3.3. Airway Stents
    • 3.3.4. Urinary Tract Stents
  • 3.4. Procedure Trends
    • 3.4.1. US
    • 3.4.2. 5EU
    • 3.4.3. Asia-Pacific
    • 3.4.4. South America
  • 3.5. Market Access
    • 3.5.1. Product Adoption
    • 3.5.2. Regulation
    • 3.5.3. Reimbursement
  • 3.6. Regulatory Issues/Recalls (2011-2014)
    • 3.6.1. Cordis Corporation Class II Recall of S.M.A.R.T Control Transhepatic Biliary Stent
  • 3.7. Mergers, Acquisitions, and Other Deals
    • 3.7.1. Medtronic Acquires Covidien
    • 3.7.2. Beijing King Health Signs Distribution Agreement With Allium Medical
    • 3.7.3. Cordis Acquires Flexible Stenting Solutions
    • 3.7.4. Allium Medical Enters Into Distribution Agreement With Meizler UCB Biopharma
    • 3.7.5. Gore and ConMed Extend Distribution Agreement
    • 3.7.6. Allium Medical Acquires Gardia Medical
    • 3.7.7. Flexible Stenting Solutions Raises Funds in Series B Financing
  • 3.8. Economic Impact

4. Unmet Needs

  • 4.1. Addressing the Complications
    • 4.1.1. Enteral Stents
    • 4.1.2. Pancreatic and Biliary Stents
    • 4.1.3. Airway Stents
    • 4.1.4. Urinary Tract Stents
  • 4.2. Overcoming Stent Design Challenges
    • 4.2.1. Stent Shortening
    • 4.2.2. Stent Fracture
    • 4.2.3. Flexibility
  • 4.3. Simplify Delivery Systems
  • 4.4. Disconnect Between Industry and Physicians
  • 4.5. Indication-Specific Stents
  • 4.6. Lack of Long-Term and Comparative Clinical Data
  • 4.7. Refocus on Pipeline Products
  • 4.8. Lack of Standardization
  • 4.9. Cost-Containment
  • 4.10. Need for An International Procedure Registry

5. Market Opportunity Analysis

  • 5.1. Improve Stent Systems
  • 5.2. Biodegradable Stents
  • 5.3. Drug-Eluting Stents
  • 5.4. Radiosensitization
  • 5.5. Customized Stents
  • 5.6. Emerging Markets

6. Market Drivers and Barriers

  • 6.1. Driver: Rising Disease Prevalence
    • 6.1.1. Cancer
    • 6.1.2. Urolithiasis
  • 6.2. Driver: Non-Malignant Stenting Applications to Drive the Market
    • 6.2.1. Drainage
    • 6.2.2. Bariatric Surgery
    • 6.2.3. Neoadjuvant Treatment
    • 6.2.4. Benign Strictures
  • 6.3. Driver: Fully-Covered, Removable Metal Stents To Drive Future Growth
  • 6.4. Driver: Preference for Minimally-Invasive Solutions
  • 6.5. Driver: Increased Life Expectancy
  • 6.6. Driver: Technological Advancements
  • 6.7. Driver: Patient Demand and Awareness
  • 6.8. Driver: Rising Competition and Innovation
  • 6.9. Barrier: Availability of Venture Capital
  • 6.10. Barrier: Burden of Rising Regulation
  • 6.11. Barrier: Proving Long-Term Efficacy
  • 6.12. Barrier: Medical Device Excise Tax

7. Competitive Assessment

  • 7.1. Gastrointestinal Stents
    • 7.1.1. Overview
    • 7.1.2. WallFlex (Boston Scientific Corporation)
    • 7.1.3. Evolution (Cook Medical)
    • 7.1.4. Niti-S (Taewoong Medical)
    • 7.1.5. Other Key Marketed Gastrointestinal Stents
  • 7.2. Biliary Stents
    • 7.2.1. Overview
    • 7.2.2. WallFlex Biliary RX (Boston Scientific Corporation)
    • 7.2.3. Cotton-Leung (Amsterdam) (Cook Medical)
    • 7.2.4. Bonastent (EndoChoice)
    • 7.2.5. Other Key Marketed Biliary Stents
  • 7.3. Airway Stents
    • 7.3.1. Overview
    • 7.3.2. Dumon (Novatech)
    • 7.3.3. Aero/Aero DV (Merit Endotek)
    • 7.3.4. Ultraflex (Boston Scientific Corporation)
    • 7.3.5. Other Key Marketed Airway Stents
  • 7.4. Urinary Tract Stents
    • 7.4.1. Overview
    • 7.4.2. Polaris Ultra (Boston Scientific Corporation)
    • 7.4.3. InLay Optima (C.R. Bard)
    • 7.4.4. Other Key Marketed Urinary Tract Stents

8. Clinical Trials to Watch

  • 8.1. Overview
  • 8.2. Enteral Stents
  • 8.3. Pancreatic and Biliary Stents
  • 8.4. Airway Stents
  • 8.5. Urinary Tract Stents

9. Current and Future Players

  • 9.1. Trends in Corporate Strategy
  • 9.2. Company Profiles
    • 9.2.1. Allium Medical
    • 9.2.2. Boston Scientific Corporation
    • 9.2.3. ConMed
    • 9.2.4. Cook Medical
    • 9.2.5. C.R. Bard
    • 9.2.6. Ella-CS
    • 9.2.7. Merit Endotek
    • 9.2.8. M.I. Tech
    • 9.2.9. Micro-Tech (Nanjing)
    • 9.2.10. Medtronic (Covidien)
    • 9.2.11. Novatech
    • 9.2.12. Olympus
    • 9.2.13. Taewoong Medical
    • 9.2.14. Xlumena
    • 9.2.15. Other Companies

10. Market Outlook

  • 10.1. Company Market Share
    • 10.1.1. US
    • 10.1.2. 5EU
    • 10.1.3. South America
    • 10.1.4. Asia-Pacific
  • 10.2. By Market Segment
    • 10.2.1. Global Overview
    • 10.2.2. Enteral Stents
    • 10.2.3. Pancreatic and Biliary Stents
    • 10.2.4. Airway Stents
    • 10.2.5. Urinary Tract Stents
  • 10.3. By Geography
    • 10.3.1. Global Overview
    • 10.3.2. US
    • 10.3.3. EU
    • 10.3.4. South America
    • 10.3.5. Asia-Pacific

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Research Methodology
    • 11.3.1. Overview
    • 11.3.2. Coverage
    • 11.3.3. Secondary Research
  • 11.4. Physicians and Specialists Included in this Study
  • 11.5. Primary Research
    • 11.5.1. Primary Research - Key Opinion Leader Interviews
    • 11.5.2. Primary Research - Physician and Industry Interviews
    • 11.5.3. Expert Panel Validation
  • 11.6. Forecasting Methodology
  • 11.7. About the Authors
    • 11.7.1. Analysts
    • 11.7.2. Global Head of Healthcare
  • 11.8. About MediPoint
  • 11.9. About GlobalData
  • 11.10. Disclaimer

List of Tables

  • Table 1: Ideal Characteristics of a Stent
  • Table 2: Comparison of Silicone and Metal Airway Stents
  • Table 3: Enteral Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Table 4: Pancreatic and Biliary Stents Procedure Volumes Forecast for the US, 2011-2021
  • Table 5: Airway Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Table 6: Urinary Tract Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Table 7: Enteral Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 8: Pancreatic and Biliary Stents Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 9: Airway Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 10: Urinary Tract Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Table 11: Enteral Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Table 12: Pancreatic and Biliary Stents Procedure Volumes Forecast for APAC, 2011-2021
  • Table 13: Airway Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Table 14: Urinary Tract Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Table 15: Enteral Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Table 16: Pancreatic and Biliary Stents Procedure Volumes Forecast for South America, 2011-2021
  • Table 17: Airway Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Table 18: Urinary Tract Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Table 19: GPOs in the US and EU
  • Table 20: Regulatory Differences Between the US and EU for Obtaining Approval for Medical Devices
  • Table 21: Medicare National Average Reimbursement Rates for Non-Vascular Stenting Procedures, 2014
  • Table 22: Direct, Indirect, and Intangible Costs of Non-Vascular Stenting
  • Table 23: WallFlex Family Stent Product Portfolio
  • Table 24: WallFlex Stent Family SWOT Analysis
  • Table 25: Evolution Family Stent Product Portfolio
  • Table 26: Evolution Stent Family SWOT Analysis
  • Table 27: Niti-S Family Stent Product Portfolio
  • Table 28: Niti-S Stent Family SWOT Analysis
  • Table 29: Gastrointestinal Stents, Other Key Marketed Products
  • Table 30: WallFlex Biliary RX Stent Product Portfolio
  • Table 31: WallFlex Biliary RX Stent SWOT Analysis
  • Table 32: Cotton-Leung Stent Product Portfolio
  • Table 33: Cotton-Leung Stent SWOT Analysis
  • Table 34: Bonastent Product Portfolio
  • Table 35: Bonastent Stent SWOT Analysis
  • Table 36: Biliary Stents, Other Key Marketed Products
  • Table 37: Dumon Stent Product Portfolio
  • Table 38: Dumon Stent SWOT Analysis
  • Table 39: Aero/Aero DV Stent Product Portfolio
  • Table 40: Aero/Aero DV Stents SWOT Analysis
  • Table 41: Ultraflex Stent Product Portfolio
  • Table 42: Ultraflex Stent SWOT Analysis
  • Table 43: Airway Stents, Other Key Marketed Products
  • Table 44: Polaris Ultra Stent Product Portfolio
  • Table 45: Polaris Ultra Stent SWOT Analysis
  • Table 46: InLay Optima Stent Product Portfolio
  • Table 47: InLay Optima SWOT Analysis
  • Table 48: Urinary Tract Stents, Other Key Marketed Products
  • Table 49: Major Clinical Trials for Enteral Stents
  • Table 50: Major Clinical Trials for Pancreatic and Biliary Stents
  • Table 51: Major Clinical Trial for Airway Stents
  • Table 52: Company Profile - Allium Medical
  • Table 53: Allium Medical's Marketed Non-Vascular Stent Products
  • Table 54: SWOT Analysis - Allium Medical
  • Table 55: Company Profile - Boston Scientific Corporation
  • Table 56: Boston Scientific Corporation's Marketed Non-Vascular Stent Products
  • Table 57: SWOT Analysis - Boston Scientific Corporation
  • Table 58: Company Profile - ConMed
  • Table 59: ConMed, Key Marketed Non-Vascular Stent Products
  • Table 60: SWOT Analysis - ConMed
  • Table 61: Company Profile - Cook Medical
  • Table 62: Cook Medical, Key Marketed Non-Vascular Stent Products
  • Table 63: SWOT Analysis - Cook Medical
  • Table 64: Company Profile - C.R. Bard
  • Table 65: C.R. Bard, Key Marketed Non-Vascular Stent Products
  • Table 66: SWOT Analysis - C.R. Bard
  • Table 67: Company Profile - Ella-CS
  • Table 68: Ella-CS, Key Marketed Non-Vascular Stent Products
  • Table 69: SWOT Analysis - Ella-CS
  • Table 70: Company Profile - Merit Endotek
  • Table 71: Merit Endotek's Key Marketed Non-Vascular Stent Products
  • Table 72: SWOT Analysis - Merit Endotek
  • Table 73: SWOT Analysis - M.I. Tech
  • Table 74: Company Profile - Micro-Tech (Nanjing)
  • Table 75: Micro-Tech (Nanjing), Key Marketed Non- Vascular Stent Products
  • Table 76: SWOT Analysis - Micro-Tech (Nanjing)
  • Table 77: Medtronic (Covidien) Marketed Non-Vascular Stent Products
  • Table 78: SWOT Analysis - Medtronic (Covidien)
  • Table 79: Company Profile - Novatech
  • Table 80: Novatech's Marketed Non-Vascular Stent Products
  • Table 81: SWOT Analysis - Novatech
  • Table 82: Company Profile - Olympus
  • Table 83: Olympus' Key Marketed Non-Vascular Stent Products
  • Table 84: SWOT Analysis - Olympus
  • Table 85: Company Profile - Taewoong Medical
  • Table 86: Taewoong Medical Marketed Products
  • Table 87: SWOT Analysis - Taewoong Medical
  • Table 88: Company Profile - Xlumena
  • Table 89: Xlumena's Key Marketed Non-Vascular Stent Products
  • Table 90: SWOT Analysis - Xlumena
  • Table 91: Other Companies Involved in the Non-Vascular Stents Market, 2014
  • Table 92: Non-Vascular Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 93: Enteral Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 94: Pancreatic and Biliary Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 95: Airway Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 96: Urinary Tract Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 97: Non-Vascular Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Table 98: Non-Vascular Stents Sales ($m) Forecast for the US, 2011-2021
  • Table 99: Non-Vascular Stents Sales ($m) Forecast for the EU, 2011-2021
  • Table 100: Non-Vascular Stents Sales ($m) Forecast for France, 2011-2021
  • Table 101: Non-Vascular Stents Sales ($m) Forecast for Germany, 2011-2021
  • Table 102: Non-Vascular Stents Sales ($m) Forecast for Italy, 2011-2021
  • Table 103: Non-Vascular Stents Sales ($m) Forecast for Spain, 2011-2021
  • Table 104: Non-Vascular Stents Sales ($m) Forecast for the UK, 2011-2021
  • Table 105: Non-Vascular Stents Sales ($m) Forecast for Brazil, 2011-2021
  • Table 106: Non-Vascular Stents Sales ($m) Forecast for APAC, 2011-2021
  • Table 107: Non-Vascular Stents Sales ($m) Forecast for Japan, 2011-2021
  • Table 108: Non-Vascular Stents Sales ($m) Forecast for China, 2011-2021
  • Table 109: Non-Vascular Stents Sales ($m) Forecast for India, 2011-2021
  • Table 110: Non-Vascular Stents - Primary Call Count by Country
  • Table 111: Non-Vascular Stents - Primary Call Count by Type

List of Figures

  • Figure 1: Enteral Stent - Esophageal
  • Figure 2: Biliary Stent
  • Figure 3: Bronchial Stent
  • Figure 4: Prostatic and Urethral Stents
  • Figure 5: Development Timeline for Esophageal Stents
  • Figure 6: Development Timeline for Gastroduodenal Stents
  • Figure 7: Development Timeline for Colorectal Stents
  • Figure 8: Enteral Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 9: Enteral Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 10: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 11: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 12: Airway Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 13: Airway Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 14: Urinary Tract Stenting Procedure Volumes Forecast for the US, 2011-2021
  • Figure 15: Urinary Tract Stenting Procedure Volumes Forecast for the US By Stent Type, 2013 and 2021
  • Figure 16: Enteral Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 17: Enteral Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 18: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 19: Pancreatic and Biliary Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 20: Airway Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 21: Airway Stenting Procedure Volumes Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 22: Urinary Tract Stenting Procedure Volumes Forecast for the 5EU, 2011-2021
  • Figure 23: Urinary Tract Stenting Procedures Forecast for the 5EU By Stent Type, 2013 and 2021
  • Figure 24: Enteral Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 25: Enteral Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 26: Pancreatic and Biliary Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 27: Pancreatic and Biliary Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 28: Airway Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 29: Airway Stenting Procedure Volumes Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 30: Urinary Tract Stenting Procedure Volumes Forecast for APAC, 2011-2021
  • Figure 31: Urinary Tract Stenting Procedures Forecast for APAC By Stent Type, 2013 and 2021
  • Figure 32: Enteral Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 33: Enteral Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021
  • Figure 34: Pancreatic and Biliary Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 35: Pancreatic and Biliary Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021
  • Figure 36: Airway Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 37: Airway Stenting Procedure Volumes Forecast for South America By Stent Type, 2013 and 2021
  • Figure 38: Urinary Tract Stenting Procedure Volumes Forecast for South America, 2011-2021
  • Figure 39: Urinary Tract Stenting Procedures Forecast for South America By Stent Type, 2013 and 2021
  • Figure 40: US Non-Vascular Stents Market, By Company Share, 2013
  • Figure 41: 5EU Non-Vascular Stents Market, By Company Share, 2013
  • Figure 42: South American Non-Vascular Stents Market, By Company Share, 2013
  • Figure 43: APAC Non-Vascular Stents Market, By Company Share, 2013
  • Figure 44: Non-Vascular Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 45: Enteral Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 46: Pancreatic and Biliary Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 47: Airway Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 48: Urinary Tract Stents Sales ($m) Forecast for the 10MM, 2011-2021
  • Figure 49: Non-Vascular Stents Sales Forecast for the 10MM, 2011-2021
  • Figure 50: Non-Vascular Stents Sales ($m) Forecast for the US, 2011-2021
  • Figure 51: US Non-Vascular Stents Market, By Segment, 2013 and 2021
  • Figure 52: Non-Vascular Stents Sales ($m) Forecast for the EU, 2011-2021
  • Figure 53: Non-Vascular Stents Sales ($m) Forecast for France, 2011-2021
  • Figure 54: French Non-Vascular Stents Market, 2013 and 2021
  • Figure 55: Non-Vascular Stents Sales ($m) Forecast for Germany, 2011-2021
  • Figure 56: German Non-Vascular Stents Market, 2013 and 2021
  • Figure 57: Non-Vascular Stents Sales ($m) Forecast for Italy, 2011-2021
  • Figure 58: Italian Non-Vascular Stents Market, 2013 and 2021
  • Figure 59: Non-Vascular Stents Sales ($m) Forecast for Spain, 2011-2021
  • Figure 60: Spanish Non-Vascular Stents Market, 2013 and 2021
  • Figure 61: Non-Vascular Stents Sales ($m) Forecast for the UK, 2011-2021
  • Figure 62: UK Non-Vascular Stents Market, 2013 and 2021
  • Figure 63: Non-Vascular Stent Sales ($m) Forecast for Brazil, 2011-2021
  • Figure 64: Brazilian Non-Vascular Stents Market, 2013 and 2021
  • Figure 65: Non-Vascular Stents Sales ($m) Forecast for APAC, 2011-2021
  • Figure 66: Nonvascular Stents Sales ($m) Forecast for Japan, 2011-2021
  • Figure 67: Japanese Nonvascular Stents Market, 2013 and 2021
  • Figure 68: Non-Vascular Stents Sales ($m) Forecast for China, 2011-2021
  • Figure 69: Chinese Non-Vascular Stents Market, 2013 and 2021
  • Figure 70: Non-Vascular Stents ($m) Forecast for India, 2011-2021
  • Figure 71: Indian Non-Vascular Stents Market, 2013 and 2021
  • Figure 72: Non-Vascular Stents - Primary Call Count by Country
  • Figure 73: Non-Vascular Stents - Primary Call Count by Type
Back to Top